window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 29, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Cell Therapy

  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    CERo reports early safety signals and platelet transfusion-free interval in Phase 1 AML trial

    CERo Therapeutics has reported early clinical findings from its ongoing [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Opinion & Events

    ICON 2025 global biotech survey shows China leading innovation and highlights Western opportunities

    ICON plc has released findings from its 2025 global biotech [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas

    Cue Biopharma and ImmunoScape partner on novel in vivo cell therapy for solid tumours

    Cue Biopharma and ImmunoScape have entered an exclusive collaboration and [...]

    May 5, 2026
  • Advanced Therapies,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    NurExone joins ARMI BioFab Startup Lab to boost US regenerative manufacturing

    NurExone Biologic Inc has been accepted into the BioFab Startup [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Therapeutic Areas

    Minovia Therapeutics gains FDA orphan drug designation for MNV-201 in myelodysplastic syndrome

    Minovia Therapeutics has received orphan drug designation from the US [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory

    Alvarez & Marsal appointed to oversee TC BioPharm as sale of business and assets begins

    Alvarez & Marsal has been appointed as joint administrators of [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Therapeutic Areas

    Orca Bio’s Orca-T receives FDA Priority Review for blood cancer treatment

    The US Food and Drug Administration (FDA) has accepted for [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    CTMC and Einstein Hospital Israelita launch global cell therapy alliance

    CTMC, a joint venture between Resilience and MD Anderson Cancer [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    BioGrad unveils state-of-the-art Liverpool bio-manufacturing centre to drive cell and gene therapy growth in the North

    BioGrad has announced plans for a new Centre of Bio-Manufacturing [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Persista Bio wins NIH funding to advance O2Line cell therapy

    Persista Bio has been awarded two grants from the US [...]

    May 5, 2026
Previous123Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Phase 2 trial begins for fetal growth restriction therapy with no approved drug treatments available
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Oral GLP-1 candidate CX11 achieves 11.5% weight loss in US Phase 2 obesity trial
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
  • NICE recommends cemiplimab for recurrent or metastatic cervical cancer
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top